MAPT and Alzheimer disease: These results are consistent with those of other authors who have demonstrated that rapamycin offers neuroprotection in in vitro models of Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s (PD) disease and in in vivo models of AD, reducing β-amyloid and tau accumulation and improving cognitive function [68].